SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	20.52	10.5	8.9	56.57	15.05	39.55
Short-Term Investments	86.87	86.09	11.86	-	-	-
Cash & Short-Term Investments	107.39	96.59	20.76	56.57	15.05	39.55
Cash Growth	735.71%	365.27%	-63.30%	275.93%	-61.95%	213.59%
Accounts Receivable	-	-	-	-	5.56	8.01
Other Receivables	1.56	0.95	0.05	-	-	-
Total Trade Receivables	1.56	0.95	0.05	-	5.56	8.01
Other Current Assets	3.84	3.51	2.98	2.34	1.49	2.64
Total Current Assets	112.78	101.05	23.79	58.91	22.1	50.19
Net Property, Plant & Equipment	20.17	19.4	19.92	24.68	28.34	30.95
Long-Term Investments	110.24	46.89	-	-	-	-
Other Long-Term Assets	5.28	5.46	0.48	0.35	0.47	-
Total Assets	248.47	172.81	44.2	83.94	50.9	81.14

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	3.54	3.15	1.69	0.95	3.68	4.46
Accrued Expenses	5.39	6.58	5.47	6.69	9.92	12.46
Short-Term Debt	-	-	0.28	1.05	0.77	-
Current Portion of Long-Term Debt	-	-	-	-	-	1.8
Current Portion of Leases	0.92	0.95	0.54	0.8	0.62	1.3
Unearned Revenue	-	-	-	1.32	-	0.1
Other Current Liabilities	-	-	-	-	-	6.34
Total Current Liabilities	9.85	10.68	7.98	10.81	14.99	26.46
Long-Term Debt	-	-	-	-	0.54	-
Long-Term Leases	5.25	5	3.86	4.05	3.99	1.65
Other Long-Term Liabilities	6.12	5.64	6.39	11.77	0.32	-
Total Long-Term Liabilities	11.37	10.63	10.25	15.83	4.85	1.65
Total Liabilities	21.22	21.32	18.23	26.64	19.85	28.11

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Preferred Stock	0	0	0	0	-	-
Common Stock	0.01	0	0	0	0	-
Treasury Stock	-5.52	-5.52	-5.52	-5.52	-5.52	-
Additional Paid-in Capital	362.75	267.72	155.79	152.86	84.45	-
Accumulated Other Comprehensive Income	-0.22	0.19	-0.14	0.03	-	-
Retained Earnings	-129.76	-110.9	-124.17	-90.06	-47.87	-
Shareholders' Equity	227.25	151.49	25.97	57.3	31.06	-
Total Liabilities & Equity	248.47	172.81	44.2	83.94	50.9	28.11

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	6.17	5.95	4.67	5.91	5.93	4.75
Net Cash (Debt)	101.22	90.64	16.09	50.66	9.12	34.79
Net Cash Growth	1568.24%	463.28%	-68.23%	455.59%	-73.79%	305.50%
Net Cash Per Share	1.37	1.48	1.74	9.18	2.10	12.73
Book Value	227.25	151.49	25.97	57.3	31.06	0
Book Value Per Share	3.08	2.47	2.80	10.38	7.14	-
Tangible Book Value	227.25	151.49	25.97	57.3	31.06	0
Tangible Book Value Per Share	3.08	2.47	2.80	10.38	7.14	-

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: May 12, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 30, 2026

Data Sources Report a data error